Phase I Trial of ONC206 for Newly Diagnosed and Recurrent Malignant CNS Tumors
A phase I trial is investigating ONC206's efficacy in treating newly diagnosed and recurrent diffuse midline gliomas.
Asset / Drug
Drug and asset intelligence for ONC206 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.